<DOC>
	<DOCNO>NCT00606710</DOCNO>
	<brief_summary>The COGENT-4 Field Following Study evaluate clinical performance Boston Scientific TELIGEN 100 HE Implantable Cardioverter Defibrillator ( ICD ) , COGNIS 100 HE Cardiac Resynchronization Therapy ICD ( CRT-D ) system RELIANCE 4-SITE defibrillation lead ( available ) . An optional sub-study also evaluate clinical performance Reverse Mode Switch ( RMS ) feature TELIGEN 100 HE DR ICD .</brief_summary>
	<brief_title>Cognis Teligen 100 HE Reliance Quadripolar Defibrillation Lead ( 4-Site ) Field Following</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Ventricular Fibrillation</mesh_term>
	<criteria>ICD indication accord normal clinical practice ( patient receive TELIGEN 100 HE ) CRTD indication accord normal clinical practice ( patient receive COGNIS 100 HE ) Willing capable providing informed consent , undergoing device implant , participate test associate clinical investigation approve clinical investigational centre interval define protocol Geographically stable patient available followup study centre Age 18 , legal age give inform consent specific national law Documented life expectancy less six month expect undergo heart transplant within next six month Patients currently require dialysis Women pregnant plan become pregnant . Method assessment per physician discretion Enrolled concurrent study Patients implant follow lead abandon : Atrial right ventricular unipolar lead Patch defibrillation lead Noncompatible defibrillation lead ( e.g . 5/6mm )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>